Biogen Could Score a Major Win if Alzheimer's Drug Gets the Green Light

Biogen (NASDAQ: BIIB) had investors more than a little concerned in 2019. The company's efforts to win approval for its highly anticipated Alzheimer's medication, aducanumab, were met by ongoing regulatory snags, forcing the company to terminate and reboot the drug program. In March of last year, shares dropped by roughly 30% after the company threw in the towel on two different clinical studies of the drug.